...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Kidney International Reports >SAT-321 THREE-YEAR FOLLOW UP OF CYTOMEGALOVIRUS PROPHYLAXIS REGIMENS IN RENAL TRANSPLANT RECIPIENTS AS AN ECONOMY-SAVING STRATEGY: A COMPARATIVE STUDY
【24h】

SAT-321 THREE-YEAR FOLLOW UP OF CYTOMEGALOVIRUS PROPHYLAXIS REGIMENS IN RENAL TRANSPLANT RECIPIENTS AS AN ECONOMY-SAVING STRATEGY: A COMPARATIVE STUDY

机译：SAT-321肾移植受者的三年后患有肾移植受者的预防方案作为一种经济型策略：比较研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Cytomegalovirus (CMV) seropositive patients are consid-ered the most common risk group among the kidney transplant re-cipients for CMV infection. Valganciclovir (VGCV) is usuallyadministered in prophylactic dose of 900 mg once daily with the hinderof being highly expensive and causing bone marrow suppression.Despite the approved dose, many centers reported adequate efficacyand safety with low-dose VGCV (450 mg/daily), which may offer asignificant cost reduction benefit. which may provide a significant costavoidance benefit especially in low- income countries. High dosevalacyclovir (VCV) regimen (8 gm/daily) is also broadly practiced.However, some studies that prescribed low-dose VCV regimen (4 gm/daily) have reported satisfactory outcomes with fewer side effects. Toour knowledge, the long-term head-to-head comparison of both low-dose regimens is limited.
机译：介绍：Cytomegalovirus（CMV）血清阳性患者在CMV感染的肾移植重新抚养部中最常见的风险组。 valganciclovir（Vgcv）通常在每日900毫克的预防剂量中，妨碍高度昂贵并导致骨髓抑制。批准的剂量，许多中心报告了具有低剂量Vgcv（450毫克/每日）的足够的效率安全性。可能会提供尽心可取的成本效益。这可能在低收入国家提供显着的CostavoInance益处。高Dosevalacyclovir（VCV）方案（VCV）方案（8克/每日）也广泛地实施。然而，一些规定低剂量VCV方案（4克/每日）的研究报告了令人满意的副作用。为了知识，低剂量方案的长期头到头比较有限。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号